(Total Views: 1492)
Posted On: 08/29/2020 6:13:24 PM
Post# of 154804
Saturday Musings
As a group, we Investors seem to be spending a lot of time focused on uplisting, typos in the press releases and which direction NP looks when he speaks.
Don't forget we are the only drug to that currently has clinically/statistically significant data. (I don't count Rems fake trial)
Don't forget that our statistically significant is in the NEWS2 metric, which is becoming widely accepted as the benchmark metric for predicting the progression of COVID. This likely indicates that Leronlimab will show good results through the entire spectrum of COVID.
Don't forget we also have statistically significant data in HIV, and are due to have an FDA response to the type A meeting soon.
Don't forget that Leronlimab has shown, in a small sample, to reduce circulating tumor cells to zero in cancer patients with CCR5 expression.
Don't forget that we have dozens of other indications that we may be successful in.
Don't forget that we have an impeccable safety profile.
In my opinion, any shenanigans that are occuring will eventually be overwhelmed by a groundswell of support. I've heard many stories of drugs being derailed by BP, but none with this much potential. I simply do not think Leronlimab can be stopped.
It's just a matter of when.
As a group, we Investors seem to be spending a lot of time focused on uplisting, typos in the press releases and which direction NP looks when he speaks.
Don't forget we are the only drug to that currently has clinically/statistically significant data. (I don't count Rems fake trial)
Don't forget that our statistically significant is in the NEWS2 metric, which is becoming widely accepted as the benchmark metric for predicting the progression of COVID. This likely indicates that Leronlimab will show good results through the entire spectrum of COVID.
Don't forget we also have statistically significant data in HIV, and are due to have an FDA response to the type A meeting soon.
Don't forget that Leronlimab has shown, in a small sample, to reduce circulating tumor cells to zero in cancer patients with CCR5 expression.
Don't forget that we have dozens of other indications that we may be successful in.
Don't forget that we have an impeccable safety profile.
In my opinion, any shenanigans that are occuring will eventually be overwhelmed by a groundswell of support. I've heard many stories of drugs being derailed by BP, but none with this much potential. I simply do not think Leronlimab can be stopped.
It's just a matter of when.
(21)
(0)
